TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 196 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $207,765 | +159.2% | 2,761 | -7.5% | 0.01% | +200.0% |
| Q1 2022 | $80,147 | -86.0% | 2,985 | -75.2% | 0.00% | -62.5% |
| Q4 2021 | $574,070 | -28.2% | 12,035 | 0.0% | 0.01% | -33.3% |
| Q3 2021 | $799,485 | -18.8% | 12,035 | -4.7% | 0.01% | -14.3% |
| Q2 2021 | $984,924 | +3.1% | 12,624 | +25.0% | 0.01% | 0.0% |
| Q1 2021 | $955,643 | -25.2% | 10,103 | -3.6% | 0.01% | -26.3% |
| Q4 2020 | $1,276,866 | +47.8% | 10,479 | +6.0% | 0.02% | +26.7% |
| Q3 2020 | $863,816 | +54.2% | 9,888 | +14.0% | 0.02% | +50.0% |
| Q2 2020 | $560,318 | +40.9% | 8,675 | -2.5% | 0.01% | +25.0% |
| Q1 2020 | $397,563 | -26.3% | 8,902 | +2.8% | 0.01% | -11.1% |
| Q4 2019 | $539,618 | +351.2% | 8,663 | +172.3% | 0.01% | +350.0% |
| Q3 2019 | $119,606 | +323.5% | 3,181 | +358.4% | 0.00% | – |
| Q2 2019 | $28,245 | – | 694 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |